Pfizer
4/10
Pfizer has $64.6B in scheduled debt maturities. While near-term maturities are manageable at $3.0B, the total $64.6B maturity schedule represents a substantial long-term obligation. PFE shows cash covering only 0.4x of $3.0B in near-term maturities. DebtCanary scores PFE at 4/10, indicating moderate refinancing pressure.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | $3.0B |
| Year 2 (12-24 months) | N/A |
| Year 3 (24-36 months) | N/A |
| Year 4 (36-48 months) | N/A |
| Year 5 (48-60 months) | N/A |
| Beyond 5 Years | $61.6B |
| Total Scheduled Maturities | $64.6B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | 4.6% |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 0.75 |
| Cash Coverage of Near-Term Debt | 0.38x |
Recent SEC Filings
Material disclosures from Pfizer's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
| Date | Form | Details |
|---|---|---|
| 2026-04-27 | 8-K | Shareholder Vote |
| 2026-03-12 | DEFA14A | Additional proxy materials |
| 2026-03-12 | DEF 14A | Proxy statement |
| 2026-02-26 | 10-K | Annual report |
| 2026-02-03 | 8-K | Earnings Results |
| 2025-12-16 | 8-K | Reg FD Disclosure |
| 2025-11-21 | 8-K | Other Events |
| 2025-11-20 | 424B5 | Prospectus supplement — possible debt or equity issuance |
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2025-12-31.
Filing date: 2026-02-26.
Data last fetched: 2026-04-29.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Pfizer →